Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
OncoAlert and ecancer weekly round up for August 15th - 21st, 2022
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for August 15th - 21st, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
22 Aug 2022
Working to improve global cancer care access in low middle-income countries
Dr Julie Gralow, Prof Eduardo Cazap
Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )
25 Jul 2022
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDM...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show...
Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )
13 Jun 2022
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity i...
Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )
5 Jun 2022
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )
5 Jun 2022
High-dose ifosfamide standard of care for recurrent and primary refractory ewing...
Dr Martin McCabe - University of Manchester, Manchester, England
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )
5 Jun 2022
Lung cancer in India
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Lung cancer in India ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )
3 Feb 2022
OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO
Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco Fr...
OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO ( Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco Franco & Dr Kathleen Schemeler )
19 Jan 2022
OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more
Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr Nagla...
OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more ( Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr Nagla Karim, Dr Fumiko Chino, Dr Narjust Duma & Dr Nicole Kuderer )
19 Jan 2022
OncoAlert Colloquium Day 4: GI oncology and EONS
Dr Cathy Eng, Dr Yelena Janjigian, Ms Stacy Hurt, Ms Allison Rosen, Dr Mark Lewi...
OncoAlert Colloquium Day 4: GI oncology and EONS ( Dr Cathy Eng, Dr Yelena Janjigian, Ms Stacy Hurt, Ms Allison Rosen, Dr Mark Lewis, Dr Nina Niu Sanford, Mr Johan de Munter & Dr Merel Van Klinken )
19 Jan 2022